These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

800 related items for PubMed ID: 21080348

  • 1. Identification of biomarkers that predict response to treatment of lupus nephritis with mycophenolate mofetil or pulse cyclophosphamide.
    Dall'Era M, Stone D, Levesque V, Cisternas M, Wofsy D.
    Arthritis Care Res (Hoboken); 2011 Mar; 63(3):351-7. PubMed ID: 21080348
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Mycophenolate mofetil or cyclophosphamide in indian patients with lupus nephritis: Which is better? A single-center experience.
    Mendonca S, Gupta D, Ali S, Gupta P.
    Saudi J Kidney Dis Transpl; 2017 Mar; 28(5):1069-1077. PubMed ID: 28937065
    [Abstract] [Full Text] [Related]

  • 4. Outcome and predictors of renal survival in patients with lupus nephritis: Comparison between cyclophosphamide and mycophenolate mofetil.
    Joo YB, Kang YM, Kim HA, Suh CH, Kim TJ, Park YW, Lee J, Lee JH, Yoo DH, Bae SC, Lee HS, Bang SY.
    Int J Rheum Dis; 2018 May; 21(5):1031-1039. PubMed ID: 29611341
    [Abstract] [Full Text] [Related]

  • 5. Comparison of low-dose intravenous cyclophosphamide with oral mycophenolate mofetil in the treatment of lupus nephritis.
    Rathi M, Goyal A, Jaryal A, Sharma A, Gupta PK, Ramachandran R, Kumar V, Kohli HS, Sakhuja V, Jha V, Gupta KL.
    Kidney Int; 2016 Jan; 89(1):235-42. PubMed ID: 26489028
    [Abstract] [Full Text] [Related]

  • 6. Mizoribine versus mycophenolate mofetil or intravenous cyclophosphamide for induction treatment of active lupus nephritis.
    Feng X, Gu F, Chen W, Liu Y, Wei H, Liu L, Yin S, Da Z, Sun L.
    Chin Med J (Engl); 2014 Jan; 127(21):3718-23. PubMed ID: 25382325
    [Abstract] [Full Text] [Related]

  • 7. Current therapies for lupus nephritis in an ethnically heterogeneous cohort.
    Rivera TL, Belmont HM, Malani S, Latorre M, Benton L, Weisstuch J, Barisoni L, Tseng CE, Izmirly PM, Buyon JP, Askanase AD.
    J Rheumatol; 2009 Feb; 36(2):298-305. PubMed ID: 19040310
    [Abstract] [Full Text] [Related]

  • 8. Randomized controlled trial of pulse intravenous cyclophosphamide versus mycophenolate mofetil in the induction therapy of proliferative lupus nephritis.
    Ong LM, Hooi LS, Lim TO, Goh BL, Ahmad G, Ghazalli R, Teo SM, Wong HS, Tan SY, Shaariah W, Tan CC, Morad Z.
    Nephrology (Carlton); 2005 Oct; 10(5):504-10. PubMed ID: 16221103
    [Abstract] [Full Text] [Related]

  • 9. Induction therapy with short-term high-dose intravenous cyclophosphamide followed by mycophenolate mofetil in proliferative lupus nephritis.
    Arends S, Berden JH, Grootscholten C, Derksen RH, Berger SP, de Sévaux RG, Voskuyl AE, Bijl M, Dutch Working Party on SLE.
    Neth J Med; 2014 Nov; 72(9):481-90. PubMed ID: 25431394
    [Abstract] [Full Text] [Related]

  • 10. Low dose mycophenolate mofetil versus cyclophosphamide in the induction therapy of lupus nephritis in Nepalese population: a randomized control trial.
    Sedhain A, Hada R, Agrawal RK, Bhattarai GR, Baral A.
    BMC Nephrol; 2018 Jul 11; 19(1):175. PubMed ID: 29996800
    [Abstract] [Full Text] [Related]

  • 11. Nonrenal disease activity following mycophenolate mofetil or intravenous cyclophosphamide as induction treatment for lupus nephritis: findings in a multicenter, prospective, randomized, open-label, parallel-group clinical trial.
    Ginzler EM, Wofsy D, Isenberg D, Gordon C, Lisk L, Dooley MA, ALMS Group.
    Arthritis Rheum; 2010 Jan 11; 62(1):211-21. PubMed ID: 20039429
    [Abstract] [Full Text] [Related]

  • 12. Mycophenolate mofetil vs cyclophosphamide therapy for patients with diffuse proliferative lupus nephritis.
    Hu W, Liu Z, Chen H, Tang Z, Wang Q, Shen K, Li L.
    Chin Med J (Engl); 2002 May 11; 115(5):705-9. PubMed ID: 12133539
    [Abstract] [Full Text] [Related]

  • 13. Induction therapies for class IV lupus nephritis with non-inflammatory necrotizing vasculopathy: mycophenolate mofetil or intravenous cyclophosphamide.
    Wang J, Hu W, Xie H, Zhang H, Chen H, Zeng C, Liu Z, Li L.
    Lupus; 2007 May 11; 16(9):707-12. PubMed ID: 17728363
    [Abstract] [Full Text] [Related]

  • 14. Outcomes of multitarget therapy using mycophenolate mofetil and tacrolimus for refractory or relapsing lupus nephritis.
    Choi CB, Won S, Bae SC.
    Lupus; 2018 May 11; 27(6):1007-1011. PubMed ID: 29448881
    [Abstract] [Full Text] [Related]

  • 15. Multitarget therapy of mycophenolate mofetil and cyclosporine A for induction treatment of refractory lupus nephritis.
    Jesus D, Rodrigues M, da Silva JAP, Inês L.
    Lupus; 2018 Jul 11; 27(8):1358-1362. PubMed ID: 29448882
    [Abstract] [Full Text] [Related]

  • 16. Mycophenolate mofetil and intravenous cyclophosphamide are similar as induction therapy for class V lupus nephritis.
    Radhakrishnan J, Moutzouris DA, Ginzler EM, Solomons N, Siempos II, Appel GB.
    Kidney Int; 2010 Jan 11; 77(2):152-60. PubMed ID: 19890271
    [Abstract] [Full Text] [Related]

  • 17. Long-term outcomes of lupus nephritis treated with regimens based on cyclophosphamide and mycophenolate mofetil.
    Prasad N, Kurian J, Agarwal V, Bhadauria D, Behera M, Yacha M, Kushwaha R, Agrawal V, Jain M, Gupta A.
    Lupus; 2020 Jul 11; 29(8):845-853. PubMed ID: 32437258
    [Abstract] [Full Text] [Related]

  • 18. Hydroxychloroquine use predicts complete renal remission within 12 months among patients treated with mycophenolate mofetil therapy for membranous lupus nephritis.
    Kasitanon N, Fine DM, Haas M, Magder LS, Petri M.
    Lupus; 2006 Jul 11; 15(6):366-70. PubMed ID: 16830883
    [Abstract] [Full Text] [Related]

  • 19. Efficacy of mycophenolate mofetil in adolescent patients with lupus nephritis: evidence from a two-phase, prospective randomized trial.
    Sundel R, Solomons N, Lisk L, Aspreva Lupus Management Study (ALMS) Group.
    Lupus; 2012 Nov 11; 21(13):1433-43. PubMed ID: 22922564
    [Abstract] [Full Text] [Related]

  • 20. Early response to immunosuppressive therapy predicts good renal outcome in lupus nephritis: lessons from long-term followup of patients in the Euro-Lupus Nephritis Trial.
    Houssiau FA, Vasconcelos C, D'Cruz D, Sebastiani GD, de Ramon Garrido E, Danieli MG, Abramovicz D, Blockmans D, Mathieu A, Direskeneli H, Galeazzi M, Gül A, Levy Y, Petera P, Popovic R, Petrovic R, Sinico RA, Cattaneo R, Font J, Depresseux G, Cosyns JP, Cervera R.
    Arthritis Rheum; 2004 Dec 11; 50(12):3934-40. PubMed ID: 15593207
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 40.